Supply Chain Intelligence

Harmony Biosciences Holdings, Inc. Supply Chain

HRMY supply chain intelligence for Harmony Biosciences Holdings, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

HRMY ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

13Suppliers
23Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Harmony Biosciences Holdings, Inc. (HRMY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

40Total relationships
3Distinct source URLs
12High confidence
0.750Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Harmony Biosciences Holdings, Inc. Suppliers

TickerNameConfidenceEvidence
CAH Cardinal Health, Inc. 92% Reciprocal relationship from CAH graph: Reciprocal relationship from HRMY graph: (“API”). ● Corden Pharma Chenôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manu…
CAH Cardinal Health, Inc. 92% (“API”). ● Corden Pharma Chenôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manufactures our API. ● Procos, S.p.A. operates as an alternate drug substance manufa…
HEON-UK-LIMITED HEON-UK-LIMITED 92% Heon UK Limited, a CDMO owned by Thermo Fisher Scientific Inc., manufactures our finished product tablets and fills them into unlabeled bottles.
INMAR-RX-SOLUTIONS-INC INMAR-RX-SOLUTIONS-INC 92% Inmar Rx Solutions, Inc., an advanced technology and data analytics company, specializes in reverse distribution of our product and manages our pharmaceutical returns and product recall, if needed.
PHARMA-PACKAGING-SOLUTIONS-LLC-DBA-TJOAPACK-LLC PHARMA-PACKAGING-SOLUTIONS-LLC-DBA-TJOAPACK-LLC 92% Pharma Packaging Solutions, LLC dba Tjoapack, LLC, handles our labeling and secondary packaging.
BIOPROJET BIOPROJET 90% Bioprojet granted to us an exclusive license to commercialize, in the United States and its territories, commonwealths, and protectorates, including Puerto Rico, a product containing pitolisant curre…
CVSI CV Sciences, Inc. 72% Reciprocal relationship from CVSI graph: Reciprocal relationship from HRMY graph: Reciprocal relationship from CVSI graph: Reciprocal relationship from HRMY graph: Reciprocal relationship from CVSI g…
DYN Dyne Therapeutics, Inc. 72% Reciprocal relationship from DYN graph: Reciprocal relationship from HRMY graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disru…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from HRMY graph: eting cost disclosure, drug price reporting and other transparency measures. Some states have enacted legislation cr…
ORANY ORANY 72% eting cost disclosure, drug price reporting and other transparency measures. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attem…
STVN Stevanato Group S.p.A. 72% Reciprocal relationship from STVN graph: t liabilities (excluding non-current advances from customers). Net working capital represents the difference between current assets and current liabilities, e…
TMO Thermo Fisher Scientific Inc. 72% Reciprocal relationship from TMO graph: Reciprocal relationship from HRMY graph: Reciprocal relationship from TMO graph: Reciprocal relationship from HRMY graph: (“API”). ● Corden Pharma Chenôve SAS,…
TMO Thermo Fisher Scientific Inc. 72% (“API”). ● Corden Pharma Chenôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manufactures our API. ● Procos, S.p.A. operates as an alternate drug substance manufa…

Harmony Biosciences Holdings, Inc. Customers

TickerNameConfidenceEvidence
ACCREDO-HEALTH-GROUP-INC ACCREDO-HEALTH-GROUP-INC 92% Accredo Health Group, Inc. accounted for 34% of gross product revenue
PANTHERX-SPECIALTY-PHARMACY-LLC PANTHERX-SPECIALTY-PHARMACY-LLC 92% PANTHERx Specialty Pharmacy LLC accounted for 27% of gross product revenue
CAH Cardinal Health, Inc. 72% (“API”). ● Corden Pharma Chenôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manufactures our API. ● Procos, S.p.A. operates as an alternate drug substance manufa…
CAH Cardinal Health, Inc. 72% Reciprocal relationship from CAH graph: Reciprocal relationship from HRMY graph: Reciprocal relationship from CAH graph: Reciprocal relationship from HRMY graph: Reciprocal relationship from CAH grap…
CVSI CV Sciences, Inc. 72% Reciprocal relationship from CVSI graph: ales for the years ended December 31, 2024 and 2023, respectively. As a result, we do not believe our financial condition and results of operations is depende…
DYN Dyne Therapeutics, Inc. 72% Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from HRMY graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from HRMY graph: Reciprocal relationship from ORAN…
ORANY ORANY 72% . Various states also independently regulate controlled substances. Though state-controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separatel…
TMO Thermo Fisher Scientific Inc. 72% (“API”). ● Corden Pharma Chenôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manufactures our API. ● Procos, S.p.A. operates as an alternate drug substance manufa…
TMO Thermo Fisher Scientific Inc. 72% Reciprocal relationship from TMO graph: Reciprocal relationship from HRMY graph: (“API”). ● Corden Pharma Chenôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manu…
XYF X Financial 72% Company’s cash and money market funds are held in six financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed t…
XYF X Financial 72% Reciprocal relationship from XYF graph: Reciprocal relationship from HRMY graph: Company’s cash and money market funds are held in six financial institutions. Due to their size, the Company believes …
CIRC-BIOSCIENCES-INC CIRC-BIOSCIENCES-INC 62% h the Company recognized as an IPR&D charge recorded in research and development within the consolidated statements of operations and comprehensive income for the year ended December 31, 2024. In Nov…
CONSYNANCE-THERAPEUTICS-INC CONSYNANCE-THERAPEUTICS-INC 62% clinical development with a Clinical Trial Application currently anticipated in mid-2025. Under the Sublicense, the Company paid Bioprojet an upfront license fee of $ 25,500 , which the Company recog…
EPYGENIX-THERAPEUTICS-INC EPYGENIX-THERAPEUTICS-INC 62% be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or comple…
HEALTH-GROUP-INC HEALTH-GROUP-INC 62% redo Health Group, Inc. (“Accredo”), which accounted for 41 % of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 33 % of gross accounts receivable; and PANTHERx Specialt…
INMAR-RX-SOLUTIONS-INC INMAR-RX-SOLUTIONS-INC 62% nôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manufactures our API. ● Patheon UK Limited, a CDMO owned by Thermo Fisher Scientific Inc., manufactures our finis…
MSN-LABORATORIES-PRIVATE-LIMITED MSN-LABORATORIES-PRIVATE-LIMITED 62% h the Company recognized as an IPR&D charge recorded in research and development within the consolidated statements of operations and comprehensive income for the year ended December 31, 2024. In Nov…
NOVITIUM-PHARMA-LLC NOVITIUM-PHARMA-LLC 62% h the Company recognized as an IPR&D charge recorded in research and development within the consolidated statements of operations and comprehensive income for the year ended December 31, 2024. In Nov…
PATHEON-UK-LIMITED PATHEON-UK-LIMITED 62% with these third parties, we may be unable to continue to successfully commercialize WAKIX and any product candidates that may receive approval. We rely and will continue to rely on certain third par…
PHARMA-PACKAGING-SOLUTIONS-LLC PHARMA-PACKAGING-SOLUTIONS-LLC 62% nôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manufactures our API. ● Patheon UK Limited, a CDMO owned by Thermo Fisher Scientific Inc., manufactures our finis…
TJOAPACK-LLC TJOAPACK-LLC 62% nôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manufactures our API. ● Patheon UK Limited, a CDMO owned by Thermo Fisher Scientific Inc., manufactures our finis…
ZYNERBA-PHARMACEUTICALS-INC ZYNERBA-PHARMACEUTICALS-INC 62% be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or comple…

Harmony Biosciences Holdings, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
HRMY-DEBT-10075 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.
HRMY-DEBT-10074 Warrants outstanding: 410239 90% xbrl warrant detail from xbrl 2020-12-31.
HRMY-DEBT Debt stack $154.0M 90% Market cache reports total debt of $154.0M.

Harmony Biosciences Holdings, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Harmony Biosciences Holdings, Inc..

Harmony Biosciences Holdings, Inc. Ownership

HolderNameConfidenceEvidence
HRMY-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 317 tracked holders.

Harmony Biosciences Holdings, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ENLT Enlight Renewable Energy Ltd 100.00 2
HTGC Hercules Capital, Inc. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
CANG Cango Inc. 100.00 2
BGC BGC Group, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
CMND Clearmind Medicine Inc. 100.00 2
BTAI BioXcel Therapeutics, Inc. 100.00 2
BRBI BRBI BR Partners S.A. 100.00 2
GEMI Gemini Space Station, Inc. 100.00 2
BLNE Beeline Holdings, Inc. 100.00 2
FENG Phoenix New Media Limited 100.00 2
CSTE Caesarstone Ltd. 100.00 2
CIB Grupo Cibest S.A. 100.00 2
CPRX Catalyst Pharmaceuticals, Inc. 100.00 2
BLSH Bullish 100.00 2
AMBR Amber International Holding Limited 100.00 2
BTDR Bitdeer Technologies Group 100.00 2
CVS CVS Health Corporation 100.00 2
RYAN Ryan Specialty Holdings, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Harmony Biosciences Holdings, Inc..

Unlock full HRMY data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
HRMY
Unlock HRMY Supply Chain Data
Verified relationships include:
CAHCardinal Health, Inc.Supplier92%
CAHCardinal Health, Inc.Supplier92%
ACCREDO-HEALTH-GROUP-INCACCREDO-HEALTH-GROUP-INCCustomer92%
PANTHERX-SPECIALTY-PHARMACY-LLCPANTHERX-SPECIALTY-PHARMACY-LLCCustomer92%
+36 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →